lavish
发表于 2025-3-23 12:20:42
Conference proceedings 1991e, in the majority of patients treatment will be conservative for a number of reasons, the cost-effectiveness of non-pharmacological approaches being of major importance. During the last two decades, drug development for ischemic heart disease has been impressive and many new compounds have been add
ADOPT
发表于 2025-3-23 14:32:10
http://reply.papertrans.cn/87/8681/868026/868026_12.png
Compassionate
发表于 2025-3-23 19:49:44
http://reply.papertrans.cn/87/8681/868026/868026_13.png
entice
发表于 2025-3-24 00:48:05
http://reply.papertrans.cn/87/8681/868026/868026_14.png
非实体
发表于 2025-3-24 02:40:08
http://reply.papertrans.cn/87/8681/868026/868026_15.png
Diverticulitis
发表于 2025-3-24 08:17:43
http://reply.papertrans.cn/87/8681/868026/868026_16.png
Disk199
发表于 2025-3-24 13:26:31
Antiischemic, antianginal, and hemodynamic effects of ULFS 49 CL (a new heart-rate-reducing agent) compound’s underlying mechanism of action to decrease heart rate can be explained by an inhibition of the i.-current, which seems to be responsible for the spontaneous depolarization of the pacemaker cells in the sino-atrial node . Like β-blockers, the substance is expected to produce a reduct
元音
发表于 2025-3-24 16:20:31
978-3-7985-0861-3Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1991
一大群
发表于 2025-3-24 20:40:07
Efficacy and duration of action of three doses of Zatebradine (ULFS 49 CL) in patients with chronicZatebradine (ULFS 49 CL) is a member of a new class of drugs, the so-called sinus node inhibitors that specifically reduce the spontaneous rate of depolarization of the pacemaker cells in the sino-atrial node , leading to a decrease in heart rate.
Obligatory
发表于 2025-3-25 03:01:59
http://reply.papertrans.cn/87/8681/868026/868026_20.png